Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis.

Autor:	Wardhani SO; Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Fajar JK; Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Wulandari L; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, 60286, Indonesia., Soegiarto G; Division of Allergy & Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, 60286, Indonesia., Purnamasari Y; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Asmiragani A; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Maliga HA; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Ilmawan M; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Seran G; Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia., Iskandar DS; Department of Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Ndapa CE; Department of Midwifery, Faculty of Medicine, University Brawijaya, Malang, 65145, Indonesia., Hamat V; Department of Midwifery, Faculty of Medicine, University Brawijaya, Malang, 65145, Indonesia., Wahyuni RA; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Cyntia LOS; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Maarang FM; Department of Nursing, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Beo YA; Department of Nursing, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Adar OA; Department of Midwifery, Faculty of Medicine, University Brawijaya, Malang, 65145, Indonesia., Rakhmadhan IM; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Shantikaratri ET; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Putri ASD; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Wahdini R; Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Broto EP; Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Surabaya, 60286, Indonesia., Suwanto AW; Department of Radiology, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Tamara F; Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Mahendra AI; Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Winoto ES; Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Krisna PA; Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia., Harapan H; Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia.
Jazyk:	angličtina
Zdroj:	F1000Research [F1000Res] 2021 Feb 03; Vol. 10, pp. 64. Date of Electronic Publication: 2021 Feb 03 (Print Publication: 2021).
DOI:	10.12688/f1000research.36396.3
Abstrakt:	Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non - RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients. Competing Interests: No competing interests were disclosed. (Copyright: © 2021 Wardhani SO et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu